Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Johan Westerbergh

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Heliyon|May 22, 2023
High-quality annotations for deep learning enabled plaque analysis in SCAPIS cardiac computed tomography angiographyErika Fagman, Jennifer Alvén, Johan Westerbergh, et al.
Platelets|June 2, 2021
Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudyThomas A Nelson, William A E Parker, Tatevik Ghukasyan Lakic, et al.
Open Heart|November 30, 2018
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trialRoopinder K Sandhu, Justin A Ezekowitz, Ziad Hijazi, et al.
Journal of the American Heart Association|September 1, 2020
Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial FibrillationZiad Hijazi, Christopher B Granger, Stefan H Hohnloser, et al.
Journal of the American Heart Association|February 9, 2018
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) TrialTymon Pol, Claes Held, Johan Westerbergh, et al.
European Heart Journal|May 30, 2025
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trialWilliam A E Parker, Thomas A Nelson, Justin Lee, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
American Heart Journal|January 5, 2021
Risk markers of incident atrial fibrillation in patients with coronary heart diseaseMaria Tomasdottir, Claes Held, Nermin Hadziosmanovic, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Heliyon|May 22, 2023
High-quality annotations for deep learning enabled plaque analysis in SCAPIS cardiac computed tomography angiographyErika Fagman, Jennifer Alvén, Johan Westerbergh, et al.
Platelets|June 2, 2021
Differential effect of clopidogrel and ticagrelor on leukocyte count in relation to patient characteristics, biomarkers and genotype: a PLATO substudyThomas A Nelson, William A E Parker, Tatevik Ghukasyan Lakic, et al.
Open Heart|November 30, 2018
Obesity paradox on outcome in atrial fibrillation maintained even considering the prognostic influence of biomarkers: insights from the ARISTOTLE trialRoopinder K Sandhu, Justin A Ezekowitz, Ziad Hijazi, et al.
Journal of the American Heart Association|September 1, 2020
Association of Different Estimates of Renal Function With Cardiovascular Mortality and Bleeding in Atrial FibrillationZiad Hijazi, Christopher B Granger, Stefan H Hohnloser, et al.
Journal of the American Heart Association|February 9, 2018
Dyslipidemia and Risk of Cardiovascular Events in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Therapy: Insights From the ARISTOTLE (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation) TrialTymon Pol, Claes Held, Johan Westerbergh, et al.
European Heart Journal|May 30, 2025
Pre-treatment lysis time of plasma-derived fibrin clots and bleeding in patients on oral anticoagulants for atrial fibrillation in the ARISTOTLE trialWilliam A E Parker, Thomas A Nelson, Justin Lee, et al.
European Heart Journal. Cardiovascular Pharmacotherapy|December 28, 2020
Heterogeneity of diabetes as a risk factor for major adverse cardiovascular events in anticoagulated patients with atrial fibrillation: an analysis of the ARISTOTLE trialRaffaele De Caterina, Giuseppe Patti, Johan Westerbergh, et al.
American Heart Journal|January 5, 2021
Risk markers of incident atrial fibrillation in patients with coronary heart diseaseMaria Tomasdottir, Claes Held, Nermin Hadziosmanovic, et al.
Pageof 2